icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
Zh5fquwQbtd3V7hQ
Listen
